Skip to main content
. Author manuscript; available in PMC: 2016 Nov 23.
Published in final edited form as: Bone Marrow Transplant. 2016 May 23;51(10):1330–1336. doi: 10.1038/bmt.2016.123

Table 2.

Prior Therapy Number of Patients
Bortezomib, Lenalidomide, Dexamethasone (BLD) 15
Bortezomib, Cyclophosphamide, Dexamethasone (BCD) 9
Bortezomib, Cyclophosphamide, Liposomal-doxarubicin, Dexamethasone (BCLD) 1
Lenolidomide, Dexamethasone (LD) 1
Bortezomib, Dexamethasone (BD) 1
BCD; BLD 1
Bortezomib, Melphalan;BCD 1
Bortezomib, Thalidomide, Dexamethasone (BTD); LD 1
BD; BLD 1
BCLD; BTD 1
LD; BLD; BCD 1
BCLD; BTD; BLD-Cisplatin, Adriamycin, Cyclophosphamide, Etoposide 1